---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007462"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:36:37.848418+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA posts Q1 net income of $14.4M; revenue surges to $36.6M on Roche termination

## Summary
- Revenue $36.6M (vs $3.2M YoY) mainly from accelerated recognition of Roche upfront and milestone payments.
- Net income $14.4M vs net loss $19.7M in Q1 2023; cash $93.0M as of March 31, 2024.
- HB-200 Phase 2/3 pivotal trial design aligned with FDA; first patient enrollment expected Q4 2024; PRIME designation from EMA.
- HB-700 IND cleared for KRAS-mutated cancers; received $10M milestone from Roche; regained full IP control.
- Mark Winderlich appointed Chief Development Officer effective April 1, 2024.

## SEC filing metadata
- accession: 0001558370-24-007462
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837024007462/0001558370-24-007462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837024007462/hook-20240509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007462
- JSON: https://secwatch.observer/filing/0001558370-24-007462.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007462.txt

## Key facts
- Earnings Releases
  HOOKIPA Pharma Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $36.6 million
  - Result: reported results
  source text: Revenue was $36.6 million for the three months ended March 31, 2024, compared to $3.2 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000155837024007462/0001558370-24-007462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.